Evidence map›Paper›PMID 39488806›Full record

ArticleBioprocess and biosystems engineering2025

Discovery and investigation of the truncation of the (GGGGS)n linker and its effect on the productivity of bispecific antibodies expressed in mammalian cells.

Yan Fang, Xi Chen, Zhen Sun, Xiaodan Yan, Lani Shi, Congcong Jin

Abstract read
PubMed Publisher
In one paragraph

Article in Bioprocess and biosystems engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yan Fang *Department of Chemistry Manufacturing and Controls, Shanghai Qilu Pharmaceutical R&D Center Limited, 576 Libing Road, Shanghai, 310115, China. yan1.fang@qilu-pharma.com.
Xi Chen *Department of Chemistry Manufacturing and Controls, Shanghai Qilu Pharmaceutical R&D Center Limited, 576 Libing Road, Shanghai, 310115, China.
Zhen SunDepartment of Chemistry Manufacturing and Controls, Shanghai Qilu Pharmaceutical R&D Center Limited, 576 Libing Road, Shanghai, 310115, China.
Xiaodan YanDepartment of Chemistry Manufacturing and Controls, Shanghai Qilu Pharmaceutical R&D Center Limited, 576 Libing Road, Shanghai, 310115, China.
Lani ShiDepartment of Chemistry Manufacturing and Controls, Shanghai Qilu Pharmaceutical R&D Center Limited, 576 Libing Road, Shanghai, 310115, China.
Congcong JinDepartment of Chemistry Manufacturing and Controls, Shanghai Qilu Pharmaceutical R&D Center Limited, 576 Libing Road, Shanghai, 310115, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein engineering is a powerful tool for designing or modifying therapeutic proteins for enhanced efficacy, increased safety, reduced immunogenicity, and improved delivery. Fusion proteins are an important group of therapeutic compounds that often require an ideal linker to combine diverse domains to fulfill the desired function. GGGGS [(G4S)n] linkers are commonly used during the engineering of proteins because of their flexibility and resistance to proteases. However, unexpected truncation was observed in the linker of a bispecific antibody, which presented challenges in terms of production and quality. In this work, a bispecific antibody containing 5*G4S was investigated, and the truncation position of the linkers was confirmed. Our investigation revealed that codon optimization, which can overcome the negative influence of a high repetition rate and high GC content in the (G4S)n linker, may reduce the truncation rate from 5-10% to 1-5%. Moreover, the probability of truncation when a shortened 3* or 4*G4S linker was used was much lower than that when a 5*G4S linker was used in mammalian cells. In the case of expressing a bispecific antibody, the bioactivity and purity of the product containing a shorter G4S linker were further investigated and are discussed.

Indexed as

Antibodies, BispecificCodonProtein EngineeringRecombinant Fusion ProteinsAnimalsCHO CellsCricetinaeCricetulusHEK293 CellsHumansImmunoglobulin GPeptidesProtein ConformationAntibodies, BispecificCodonImmunoglobulin GPeptidesRecombinant Fusion ProteinsBispecific antibodyCodon optimizationG4S linkerTruncation

Identifiers

PMID39488806

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.